A Randomized, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Niclosamide in Healthy Adults
Latest Information Update: 12 Dec 2023
At a glance
- Drugs Niclosamide (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors NeuroBo Pharmaceuticals
- 06 Dec 2023 Status changed from recruiting to completed.
- 02 May 2023 According to Neurobo media release, expected data readout is in second half of 2024.
- 08 Sep 2021 Planned End Date changed from 1 Feb 2021 to 1 Oct 2021.